Subsequent Kaplan-Meier analysis of all patients with the availabe outcome data (n = 43) demonstrated that the EFS disadvantage of patients with HOXA9 lo was quite modest and did not reach statistical significance in a log rank test ( Figure 3 B).
← all excerpts
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.
1
—
—